Stroke subarachnoïd hemorrhage
Conditions
Interventions
Therapeutic dose of nadroparine (5700IE twice daily), continued until 21 days
after initial SAH or untill discharge, compared to a standard profylactic dose
(2850IE once daily).
Sponsors
Academisch Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Adult patients suffering from an aneurysmal subarachnoid hemorrhage treated with coiling.
Exclusion criteria
Exclusion criteria: Stent-assisted coiling Contra-indications low-molecular weight heparin Proven and active COVID-19
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 30-days mortality | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate whether there is a difference in: • patients with a favourable outcome (score 0-3 on the mRS) after six months • quality of life after three and six months • cognitive functioning at three and six months after hemorrhage • the presence and severity of delayed cerebral is-chemia • the presence of cerebral (micro)infarctions on MR-imaging six months after hemorrhage • the rate of a major and non-major bleeding • the presence of major or clinically relevant non-major hemorrhagic complications after EVD/ELD placement or LP • the occurrence of venous thrombo-embolic events • the hemostatic balance and markers of activation of coagulation • markers of inflammation and coagulation • discharge destination • shunt-dependent hydrocephalus • other SAH-related complications (such as severe hyponatriaemia, delayed cerebral ischemia, postprocedural aneurysm rupture, rebleed, delirium, epilepsy, diffuse parenchymal swelling or nosocomial infections) during admission | — |
Countries
Netherlands
Outcome results
None listed